Contrive Datum Insights has published "Mirtazapine Drug Market Size, Share & Industry Analysis, By Drug type (Branded, Generic), Dosage form (Tablets, Orally Disintegrating Tablets), Application (Major Depressive Disorder, Generalized Anxiety Disorder, Insomnia, Others), Distribution channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), End user (Homecare and Retail Patients, Hospitals and Clinics), and Regional Forecast, 2026-2034". The study sizes the global mirtazapine drug market at USD 1.894 billion in 2025 and projects growth from USD 1.983 billion in 2026 to USD 2.897 billion by 2034, a compound annual growth rate of 4.85% across the forecast period.
Mirtazapine is a tetracyclic antidepressant sold as immediate-release tablets and orally disintegrating tablets, prescribed primarily for major depressive disorder and, off-label, for generalized anxiety and the sleep and appetite disturbances that accompany depression. It is manufactured almost entirely as a generic small-molecule drug today, dispensed through hospital, retail and increasingly online pharmacy channels to adult and geriatric patients under a physician's prescription. Buyers of this report are generic drug manufacturers, pharmacy benefit managers and distributors tracking volume, pricing and channel shifts in an established, off-patent CNS therapy.
Sustained prescription volume growth in treatment-resistant and complex depression
Sustained prescription volume growth in treatment-resistant and complex depression is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 4.85% a year, the drug type lines exposed to it move fastest: Generic compounds at 5.2%, taking its share of revenue from 90% to 92.7% and its value from USD 1.705 billion to USD 2.686 billion.
Where the forecast could be beaten: the bull case assumes generic price erosion slows earlier than in the base case and mental health diagnosis and treatment access in Asia Pacific and Latin America expands faster, lifting volume growth across those regions. The study puts that case at USD 3.071 billion in 2034, against USD 2.897 billion in the base.
On the downside, the bear case assumes generic-to-generic price competition intensifies further and newer antidepressants with improved tolerability profiles displace mirtazapine prescribing faster than the base case anticipates in the largest markets, which would hold 2034 revenue to USD 2.723 billion. Branded, which carries 10% of 2025 revenue, already grows at only 1.19% against the market's 4.85%, so the largest part of the base is also its slowest.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Dosage form | Tablets | 90% · USD 1.705 billion | Orally Disintegrating Tablets 8.87% |
| Application | Major Depressive Disorder | 68% · USD 1.288 billion | Insomnia 7.5% |
| Distribution channel | Retail Pharmacies | 62% · USD 1.174 billion | Online Pharmacies 9.07% |
| End user | Homecare and Retail Patients | 78% · USD 1.477 billion | — |
- Regionally, the lead sits with North America: 34% of 2025 global revenue, USD 0.644 billion rising to USD 0.898 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 26% in 2025 to 30% in 2034, with revenue growing from USD 0.492 billion to USD 0.869 billion.
- At 5% of 2025 revenue and 5% by 2034, Middle East and Africa is the smallest region throughout.
- Generic was the leading drug type line in 2025, taking 90% of revenue at USD 1.705 billion.
- Generic is projected to grow at 5.2% over the forecast period, the fastest of any drug type line.
- The United States is the largest single country market at USD 0.547 billion in 2025, 28.9% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by drug type, and by dosage form, application, distribution channel and end user. The headline total carries bear, base and bull cases at USD 2.723 billion and USD 3.071 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.